Courtesy of Benzinga.
Allergan, Inc. (NYSE: AGN) (“Allergan” or the “Company”) today filed an answer
in the United States District Court for the Central District of California
responding to Valeant Pharmaceuticals International, Inc. (“Valeant”) and
Pershing Square Capital Management, L.P.’s (“Pershing Square”) counterclaims
regarding Allergan’s statements on the unsustainability of Valeant’s
underlying business model.
The federal court case is Allergan, Inc. v. Valeant Pharmaceuticals
International, Inc., No. 14-CV-1214-DOC (ANx) (C.D. Cal.).
Posted-In: News Hedge Funds Legal Press Releases General
